Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate P is indicated for the management of bleeding disorders that involve deficiency of factor VIII and von Willebrand factor.

• Treatment of acute bleeding episodes in patients with hemophilia A.
• Prophylactic replacement therapy to prevent spontaneous bleeds in hemophilia A.
• Management of bleeding episodes in patients with von Willebrand disease types 1, 2, and 3.
• Perioperative hemostatic support for surgical or dental procedures in individuals with these clotting factor deficiencies.
• Use in combination with other clotting factor concentrates when indicated by a specialist.

Potential adverse reactions to Haemate P have been reported, ranging from mild to severe.

Common

• Headache or mild fever.
• Nausea, vomiting, or abdominal discomfort.
• Local infusion site reactions such as redness or swelling.
• Transient increase in blood pressure during infusion.
• Mild joint pain or swelling.

Serious

• Development of inhibitors (antibodies) against factor VIII or von Willebrand factor.
• Allergic reactions including rash, urticaria, or anaphylaxis.
• Thromboembolic events such as deep vein thrombosis or pulmonary embolism.

When prescribing Haemate P, clinicians should consider several precautionary measures to ensure safe use.

• Assess for a history of inhibitors to factor VIII before initiating therapy.
• Monitor for signs of allergic reactions during and after infusion.
• Evaluate cardiovascular status, especially in patients with a history of thrombosis.
• Use caution in patients with renal or hepatic impairment, adjusting dosing as needed.
• Conduct regular laboratory testing to verify factor levels and treatment efficacy.
• Avoid use in patients with known hypersensitivity to any component of the product.

Haemate P may interact with other medications, influencing clotting balance or immune response.

Avoid

• Concomitant use of other factor VIII concentrates without specialist guidance.
• Administration of high‑dose pro‑coagulant agents that could increase thrombosis risk.

Use with caution

• Antifibrinolytic agents (e.g., tranexamic acid) may enhance hemostatic effect and require monitoring.
• Immunosuppressive drugs could affect inhibitor development.
• Certain antibiotics (e.g., beta‑lactams) have been associated with hypersensitivity reactions in some patients.
• Vaccines administered shortly before or after infusion may alter immune response.